● Inclusion criteria for study part A | ● Inclusion criteria for study part B |
---|---|
● Postinfectious cough | ● Postinfectious cough |
● Syndrome of “pathogenic-wind invading lung” | ● Syndrome of “pathogenic-wind invading lung” |
● Daytime cough symptom score ≥ 2 and/or nighttime cough symptom score ≥ 2 | ● Total cough symptom score ≥ 4 |
● Persistent cough ≥ 3 weeks and ≤ 6 weeks | ● Persistent cough ≥ 3 weeks and ≤ 6 weeks |
● Age 18-65 years old | ● Age 18-65 years old |
● Agreement to participate and provision of informed consent | ● Agreement to participate and provision of informed consent |
● Exclusion criteria | |
● Body temperature > 37.3 °C | |
● Use of any medication intended to treat PIC within one week before enrollment | |
● ALT/AST > 1.5 times than the upper limit of normal reference values; Abnormal blood creatinine; Urine protein qualitative test > +; Blood leukocyte count < 3.0 × 109/L or > 10.0 × 109/L; and/or neutrophil percentage > 80% | |
● History of any severe underlying diseases (e.g. cardiovascular, hematological, hepatic, renal); or other life-threatening disabling conditions and concomitant diseases (e.g. cancer, AIDS) | |
● Pregnancy or potential pregnancy or lactation | |
● Hypersensitivity or allergy to any component of the test drug | |
● Current psychiatric disorders or legal disability | |
● Current or previous admission to other investigational drug studies within 3 months before enrollment | |
● Inability to complete the trial as decided by the investigators |